Two drugs are better than one: GSK's melanoma combo improves PFS at Phase II
This article was originally published in Scrip
Executive Summary
Combining two novel GlaxoSmithKline drugs, the selective BRAF inhibitor dabrafenib, and the selective MAPK kinase (MEK) inhibitor trametinib, significantly improved progression-free survival in a Phase II study in melanoma, new data presented at ESMO and published in the New England Journal of Medicine show.